Titan Medical Inc. Appoints Dr. Terry W. Grogg to Its Medical Advisory Board
TORONTO, ONTARIO -- (MARKET WIRE) -- 08/25/11 -- Titan Medical Inc. ("the Company") (TSX VENTURE: TMD) today announced that it has appointed Dr. Terry W. Grogg, M.D., to the Company's Medical Advisory Board.
"We are very pleased to welcome Dr. Grogg to our Medical Advisory Board," said Dr. Reiza Rayman, President of Titan Medical Inc. "The addition of Dr. Grogg strengthens our expertise in robotic Gynecologic surgery and will be a significant asset in guiding our developments to target this surgical specialty."
"I am excited about the opportunity to join Titan's prominent Medical Advisory Board and to work with the company's development team," said Dr. Terry W. Grogg. "I will look to provide valuable insight to help position the Company's efforts in enabling robotic surgical solutions in the field of Gynecological surgery and to apply my experience, having completed over 500 robotic surgeries and trained nearly 75 surgeons in robotic surgery, to ensure Amadeus Composer is a leader in this surgical area."
Dr. Terry W. Grogg, M.D., is currently a clinical instructor for resident education at Mount Carmel West and at The Ohio State University since 1992, and is a partner at Southwestern Obstetrics and Gynecology a division of MOCA, a private practice. He joined Mount Carmel West after completing his Obstetrics and Gynecology residency at Mount Carmel West. His main clinical and surgical research interests in Minimally Invasive Surgery include hysterectomies, myomectomies, excision of endometriosis, Unilateral Salpingo Oopherectomy, Bilateral Salpingo Oopherectomy, and sacrocolpopexy. He has presented his research in robotic hysterectomy at leading surgical conferences and was previously Chairman of the Department of Obstetrics and Gynecology and a Medical Director of Minimally Invasive Surgery at Mount Carmel West. He is currently a Member of Surgical Services Executive Committee at Mount Carmel West and an independent reviewer for the Journal of Minimally Invasive Gynecology. Dr. Grogg had earned his M.D. at The Ohio State University and B.S. at the University of Cincinnati.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus Composer™, a surgical system that has a uniquely designed external robot and flexible instruments, and allows surgeons to overcome constraints of surgical procedures in small to medium spaces. Amadeus Maestro™, the Company's next generation 4-armed robotic surgical system with advanced communication and training, utilizes the Titan True Touch Technology and is targeted to surgical procedures in large spaces. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The global robotic surgical market size is currently estimated to be approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2011 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext. 151) cleon@titanmedicalinc.com www.titanmedicalinc.com ICR, LLC Sherry Bertner Managing Director (646) 277-1247 Sherry.Bertner@icrinc.com
Source: Titan Medical Inc.
Released August 25, 2011